Cardiomagnyl Forte 150mg 100 tablets — Made in Germany — Free Delivery

Brand: TAKEDA PHARMA
Product Code: Cardiomagnyl Forte
Availability: In Stock

$21.88

Description

Pharmachologic effect

Antiplatelet agent.

Indications

Primary prevention of cardiovascular diseases, such as thrombosis and congestive heart failure, in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age).

Prevention of recurrent myocardial infarction and blood vessel thrombosis.

Prevention of thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty).

Unstable angina.

Composition and form of release

Active ingredients:

Acetylsalicylic acid - 75 mg / 150 mg
Magnesium hydroxide - 15.2 mg / 30.39 mg

Excipients:

Corn starch - 9.5 mg / 19.0 mg
Microcrystalline cellulose - 12.5 mg / 25.0 mg
Magnesium Stearate - 150 mcg / 305 mcg
Potato starch - 2.0 mg / 4.0 mg

Shell

Hypromellose (methylhydroxypropylcellulose 15) - 460 μg / 1.2 mg
Propylene glycol - 90 mcg / 240 mcg
Talc - 280 mcg / 720 mcg
Film-coated tablets 75 mg + 15.2 mg and 150 mg + 30.39 mg

30 or 100 tablets in brown glass vials, sealed with a white screw cap (made of polyethylene), with a built-in removable capsule with silica gel and a ring that provides control of the first opening. A label is attached to each bottle. One bottle with instructions for use is placed in a cardboard box.

Contraindications

Hypersensitivity to ASA, excipients of the preparation and other NSAIDs, cerebral hemorrhage; bleeding tendency (vitamin K deficiency, thrombocytopenia, hemorrhagic diathesis); bronchial asthma induced by the intake of salicylates and NSAIDs; erosive and ulcerative lesions of the gastrointestinal tract (in the acute phase); gastrointestinal bleeding; severe renal failure (creatinine clearance less than 10 ml / min.); pregnancy (I and III trimesters); lactation period; deficiency of glucose-6-phosphate dehydrogenase; simultaneous reception with methotrexate (more than 15 mg per week); children under 18 years of age.

Use during pregnancy and children

The use of large doses of salicylates in the first 3 months of pregnancy is associated with an increased incidence of fetal defects. In the second trimester of pregnancy, salicylates can be prescribed only with a rigorous assessment of the risks and benefits.

In the last trimester of pregnancy, salicylates in a high dose (more than 300 mg / day) cause inhibition of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and fetus, and administration just before childbirth can cause intracranial hemorrhage, especially in premature babies.

The appointment of salicylates in the last trimester of pregnancy is contraindicated.

The available clinical data are insufficient to establish the possibility or impossibility of using the preparation during breastfeeding. Before prescribing acetylsalicylic acid during lactation, the potential benefit of preparation therapy should be assessed relative to the potential risk to infants.

Side effects

The frequency of the adverse reactions listed below was determined according to the following:

very often ≥ 1/10;

often> 1/100, <1/10;

sometimes> 1/1000, <1/100;

rarely> 1/10 000, <1/1000;

very rarely <1/10 000, including isolated reports.

Allergic reactions: urticaria (often), Quincke's edema (often).

Immune system: anaphylactic reactions (sometimes).

Gastrointestinal tract: nausea (common), heartburn (very common), vomiting (common), pain in the abdomen, ulcers of the gastric and duodenal mucosa (sometimes), including perforation (rare), gastrointestinal bleeding (sometimes), increased activity of "liver" enzymes (rare), stomatitis (very rare), esophagitis (very rare), erosive lesions of the upper gastrointestinal tract (very rare), strictures (very rare), colitis (very rare) , exacerbation of intestinal irritation (very rare).

Respiratory system: bronchospasm (common)

Hematopoietic system: increased bleeding (very common), anemia (rare), hypoprothrombinemia (very rare), thrombocytopenia (very rare), neutropenia, aplastic anemia (very rare), eosinophilia (very rare), agranulocytosis (very rare).

Central nervous system: dizziness (sometimes), headache (often), insomnia (often), drowsiness (sometimes), tinnitus, intracerebral hemorrhage (rare).

Preparation interactions

With the simultaneous use of ASA enhances the effect of the following preparations:

methotrexate by reducing renal clearance and displacing it from the connection with proteins
heparin and indirect anticoagulants due to impaired platelet function and displacement of indirect anticoagulants from protein binding
thrombolytic and antiplatelet and anticoagulant preparations (ticlopidine)
digoxin due to a decrease in its renal excretion
hypoglycemic agents for oral administration (sulfonylurea derivatives) and insulin due to the hypoglycemic properties of ASA itself in high doses and displacement of sulfonylurea derivatives from the connection with blood plasma proteins
valproic acid due to its displacement from the connection with proteins

The simultaneous use of ASA with ibuprofen leads to a decrease in the cardioprotective effects of ASA.

An additive effect is observed with the simultaneous administration of ASA with ethanol (alcohol).

ASA weakens the action of uricosuric agents (benzbromarone) due to the competitive tubular elimination of uric acid.

By enhancing the elimination of salicylates, systemic glucocorticosteroids (GCS) weaken their effect.

Antacids and cholestyramine reduce the absorption of the preparations.

Dosage

The tablets are swallowed whole with water. If desired, the tablet can be broken in half, chewed or pre-ground.

Primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure, in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age):

1 tablet of Cardiomagnyl containing ASA at a dose of 150 mg on the first day, then 1 tablet of Cardiomagnyl containing ASA at a dose of 75 mg 1 time per day.

Prevention of recurrent myocardial infarction and blood vessel thrombosis:

1 tablet of Cardiomagnyl containing ASA at a dose of 75-150 mg once a day.

Prevention of thromboembolism after vascular surgery (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty):

1 tablet of Cardiomagnyl containing ASA at a dose of 75-150 mg once a day.

Unstable angina pectoris:

1 tablet of Cardiomagnyl containing ASA at a dose of 75-150 mg once a day.

Overdose

Overdose symptoms of moderate severity: nausea, vomiting, tinnitus, hearing impairment, dizziness, confusion.

Treatment: rinse the stomach, take activated charcoal. Treatment is symptomatic.

Severe overdose symptoms: fever, hyperventilation, ketoacidosis, respiratory alkalosis, coma, cardiovascular and respiratory failure, severe hypoglycemia.

1 reviews

Aurora P.

16/10/2023

text_comment

Exceptional quality. Swift shipping. A strong endorsement.